Proveris Scientific Announces Contract Test Services to Support Development of SARS-CoV-2 (COVID-19) Inhaled Drug Therapies & Vaccines

Proveris Scientific Corporation, a leading provider of services and technology to advance the science of spray and aerosol products, recently announced the availability of contract test services to support drug developers of SARS-CoV-2 (COVID-19) inhaled drug therapies and vaccines.

Orally inhaled drug products (OINDPs) have a long history of treating respiratory disease. Common dosage forms include nebulizers, dry powder inhalers (DPI), pressured metered dose inhalers (pMDI), and soft mist inhalers (SMI). Each offers its own benefits and advantages. In addition, treatment via the nasal cavity is also a popular target area to deliver vaccines and other systematic drugs.

Proveris has more than 25 years’ experience  OINDPs, specializing in human realistic in vitro characterization and thriving to improve the correlation between in vitro and in vivo studies. The company extends its experience and expertise to those developing therapies and vaccines for SARS-CoV-2 (COVID-19):

-Conducting preliminary proof-of-concept studies to confirm desired pulmonary delivery

-Making dosage form decisions and providing guidance through the product development and submission process

-Applying realistic SARS-CoV-2 (COVID-19) patients breathing profiles to a human-realistic model of the respiratory tract to predict drug deposition and infer efficacy

Recently, the US FDA pledged its support of this effort by announcing the Coronavirus Treatment Acceleration Program (CTAP), promising to utilize every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful. Proveris’s experience working with regulatory agencies and their familiarity with combination drug product guidance can also be extended to optimize project workflows and timelines.

Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, China NMPA (National Medical Products Administration), and the pharmaceutical industry to generate submission-ready data. The company operates under an ISO 9001:2015 certified quality management system and its laboratory operations are cGMP compliant.